Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case
By Blake Brittain (Reuters) – Genetic testing company Natera Inc convinced a Delaware federal jury on Monday to award it $19.3 million in damages from Invitae Corp’s ArcherDX for infringing patents related to cancer detection. The jury agreed with Natera that biotech company ArcherDX Inc’s blood-based DNA tests for detecting and monitoring cancer infringed three …
Natera wins $19 million US verdict from ArcherDX in cancer-detection patent case Read More »







